Bon Natural Life (BON) Competitors $1.52 0.00 (0.00%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.50 -0.02 (-1.64%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. BPTH, PBLA, HEPA, BPTSY, WINT, VIRX, VINC, TRVN, MYMD, and ORGSShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Bio-Path (BPTH), Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Windtree Therapeutics (WINT), Viracta Therapeutics (VIRX), Vincerx Pharma (VINC), Trevena (TRVN), MyMD Pharmaceuticals (MYMD), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Bio-Path Panbela Therapeutics Hepion Pharmaceuticals Biophytis Windtree Therapeutics Viracta Therapeutics Vincerx Pharma Trevena MyMD Pharmaceuticals Orgenesis Bio-Path (NASDAQ:BPTH) and Bon Natural Life (NYSE:BON) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Which has stronger earnings and valuation, BPTH or BON? Bon Natural Life has higher revenue and earnings than Bio-Path. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-PathN/AN/A-$16.08MN/AN/ABon Natural Life$23.84M0.01$400KN/AN/A Is BPTH or BON more profitable? Bon Natural Life's return on equity of 0.00% beat Bio-Path's return on equity.Company Net Margins Return on Equity Return on Assets Bio-PathN/A -2,842.40% -337.48% Bon Natural Life N/A N/A N/A Which has more risk & volatility, BPTH or BON? Bio-Path has a beta of -0.03, indicating that its share price is 103% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500. Does the media refer more to BPTH or BON? In the previous week, Bio-Path and Bio-Path both had 1 articles in the media. Bon Natural Life's average media sentiment score of 0.00 beat Bio-Path's score of -1.00 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Overall Sentiment Bio-Path Negative Bon Natural Life Neutral Do insiders & institutionals believe in BPTH or BON? 5.7% of Bio-Path shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 0.7% of Bio-Path shares are held by insiders. Comparatively, 26.5% of Bon Natural Life shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryBon Natural Life beats Bio-Path on 6 of the 8 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$254K$3.41B$8.39B$21.30BDividend YieldN/AN/A2.99%3.49%P/E RatioN/A9.3218.4329.64Price / Sales0.0174.524.8685.04Price / Cash0.785.6216.7925.18Price / Book0.041.185.014.55Net Income$400K$17.44M$227.17M$999.70M7 Day Performance7.80%2.94%1.14%0.58%1 Month Performance18.75%14.22%19.47%5.67%1 Year Performance-96.36%-19.25%51.80%18.25% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$1.52flatN/A-96.4%$254K$23.84M0.00100BPTHBio-Path0.4999 of 5 stars$0.10+1.0%N/A-87.8%$839KN/A0.0010Short Interest ↑PBLAPanbela Therapeutics0.0805 of 5 stars$0.16flatN/AN/A$767KN/A0.006Gap DownHEPAHepion Pharmaceuticals0.2986 of 5 stars$0.06+7.1%N/A-99.8%$709KN/A-0.0120Short Interest ↑Gap DownBPTSYBiophytisN/A$2.00flatN/AN/A$702KN/A0.0030WINTWindtree Therapeutics2.8247 of 5 stars$0.12+2.2%$350.00+283,530.5%-99.9%$452KN/A0.0030Short Interest ↓VIRXViracta Therapeutics1.2388 of 5 stars$0.01flat$1.13+11,403.1%N/A$389KN/A-0.0120VINCVincerx Pharma2.5011 of 5 stars$0.06+33.3%$40.00+66,566.7%-99.8%$314KN/A0.0060Short Interest ↑TRVNTrevena1.456 of 5 stars$0.28flat$5.00+1,718.2%N/A$264K$443K-0.0140Gap UpMYMDMyMD PharmaceuticalsN/A$0.06-16.8%N/AN/A$148KN/A0.006Gap DownHigh Trading VolumeORGSOrgenesisN/A$0.02-78.0%N/AN/A$106K$662K0.00150Gap Down Related Companies and Tools Related Companies Bio-Path Competitors Panbela Therapeutics Competitors Hepion Pharmaceuticals Competitors Biophytis Competitors Windtree Therapeutics Competitors Viracta Therapeutics Competitors Vincerx Pharma Competitors Trevena Competitors MyMD Pharmaceuticals Competitors Orgenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
